At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...

Regeneron’s treatment for age-related macular degeneration (AMD) Eylea and Eylea HD generated $5.9 billion in 2024 in the United States. Eylea sales rose just 1% YoY in 2024 as this blockbuster ...

A class action lawsuit was filed against Regeneron Pharmaceuticals, Inc. (REGN) by Levi & Korsinsky on January 7, 2025. The ...

2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...

FYB203 (aflibercept) approved in the UK for the treatment of neovascular age-related macular degeneration (nAMD) and several other severe retinal diseases UK market authorization follows successful ...

Alvotech is currently developing AVT29, a biosimilar candidate for EYLEA® HD 8 mg. Teva holds commercialization rights for AVT29 in the United States. As we have previously reported, Alvotech and ...

For example, Regeneron's (REGN) Eylea and Eylea HD, as well as Genentech's Lucentis and Vabysmo, could be considered the “previous generation” of anti-VEGF drugs. Currently, the next step for ...

US sales alone rose 10%. EYLEA/EYLEA HD generated combined US sales of $1.5 billion in Q4, capturing 46% of the anti-VEGF (vascular endothelial growth factor) market, with EYLEA HD sales reaching ...

a biosimilar candidate for Eylea ® HD (aflibercept) 8 mg. Teva also holds commercialization rights for AVT29 in the U.S. AVT06/AVT29 is a recombinant fusion protein and a biosimilar candidate to Eylea ...